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1. INTRODUCTION {#tme12667-sec-0006}
===============

Trauma is a major cause of death and disability.[1](#tme12667-bib-0001){ref-type="ref"}, [2](#tme12667-bib-0002){ref-type="ref"} In injured patients, death within 24 hours is primarily attributable to haemorrhage,[3](#tme12667-bib-0003){ref-type="ref"}, [4](#tme12667-bib-0004){ref-type="ref"}, [5](#tme12667-bib-0005){ref-type="ref"} and many of these deaths are potentially preventable.[6](#tme12667-bib-0006){ref-type="ref"}, [7](#tme12667-bib-0007){ref-type="ref"}, [8](#tme12667-bib-0008){ref-type="ref"} To optimise bleeding patients\' odds of survival, pre‐hospital treatment focuses on early haemorrhage control to avoid hypovolaemic shock and the lethal triad of acidosis, hypothermia and coagulopathy. This is commonly attempted with topical treatment,[9](#tme12667-bib-0009){ref-type="ref"} such as haemostatic dressings, tourniquets and/or pelvic binders. However, haemorrhage is often non‐compressible and cannot be controlled by topical treatment alone.[7](#tme12667-bib-0007){ref-type="ref"}, [10](#tme12667-bib-0010){ref-type="ref"}, [11](#tme12667-bib-0011){ref-type="ref"} Moreover, patients may already be in haemorrhagic shock when pre‐hospital healthcare providers arrive at a scene. Therefore, to replace (ongoing) blood loss, liberal volume replacement, typically with readily available crystalloid fluids, has been long advocated.[12](#tme12667-bib-0012){ref-type="ref"} However, this practice is associated with adverse effects including dilutional coagulopathy, acidosis, hypothermia and accelerated blood loss.[13](#tme12667-bib-0013){ref-type="ref"} In contrast, damage control resuscitation (DCR) involves restrictive fluid resuscitation, which avoids crystalloids while accepting some degree of hypotension, and is increasingly preferred until bleeding can be surgically controlled.[13](#tme12667-bib-0013){ref-type="ref"}, [14](#tme12667-bib-0014){ref-type="ref"}, [15](#tme12667-bib-0015){ref-type="ref"}, [16](#tme12667-bib-0016){ref-type="ref"}, [17](#tme12667-bib-0017){ref-type="ref"}, [18](#tme12667-bib-0018){ref-type="ref"}

Red blood cells (RBCs) provide a more effective volume expansion than crystalloids; the infusion of large volumes of crystalloids or colloids can thus be avoided. The RBCs benefit haemostasis and thrombosis[19](#tme12667-bib-0019){ref-type="ref"} and restore oxygen‐carrying capacity,[20](#tme12667-bib-0020){ref-type="ref"} thereby potentially reducing acidosis through tissue hypoxia. Military medical teams have long been transfusing blood products prior to patients\' arrival at a surgical unit.[4](#tme12667-bib-0004){ref-type="ref"}, [21](#tme12667-bib-0021){ref-type="ref"} As proposed by Jansen et al,[22](#tme12667-bib-0022){ref-type="ref"} differences in survival between civilian casualties who require massive transfusion (60%)[23](#tme12667-bib-0023){ref-type="ref"} and military casualties (93%)[22](#tme12667-bib-0022){ref-type="ref"} may be partly explained by this practice.

In recent years, civilian Emergency Medical Services (EMS) are increasingly transfusing RBCs before hospital arrival.[24](#tme12667-bib-0024){ref-type="ref"}, [25](#tme12667-bib-0025){ref-type="ref"} However, logistic and operational challenges are hampering the widespread implementation of blood transfusions in the pre‐hospital setting. Moreover, consensus regarding pre‐hospital indications for blood transfusions is lacking, and evidence regarding the efficacy of this practice is scarce. Therefore, this systematic review consists of two parts. Part 1 is a scoping review in which we systematically gathered the research done in the area of pre‐hospital transfusion of red blood cells (PHTRBC), aiming to describe the current challenges of pre‐hospital transfusion and, in particular, to evaluate which criteria are currently used to initiate PHTRBC. This review may serve as guide to derive consensus based pre‐hospital transfusion protocols and informed practice guidelines. In Part 2, the effect on patient outcomes will be systematically appraised.

2. METHODS {#tme12667-sec-0007}
==========

The review was registered at Prospero (website: <https://www.crd.york.ac.uk/prospero>, identification number: CRD42018084658) and was conducted in accordance with PRISMA‐Scr (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses---Extension for Scoping Reviews) guidelines.[26](#tme12667-bib-0026){ref-type="ref"}

2.1. *Information sources, search strategy and study selection* {#tme12667-sec-0008}
---------------------------------------------------------------

PubMed and Web of Science were searched through January 2019 using the following terms: PUBMED: ("emergency medical services"\[MeSH Terms\] OR ("emergency"\[All Fields\] AND "medical"\[All Fields\] AND "services"\[All Fields\]) OR "emergency medical services"\[All Fields\] OR "Warfare"\[Mesh\] OR "Warfare"\[All Fields\] OR combat\[All Fields\]) AND ("blood transfusion"\[MeSH Terms\] OR ("blood"\[All Fields\] AND "transfusion"\[All Fields\]) OR "blood transfusion"\[All Fields\]). WEB OF SCIENCE: TOPIC: (((emergency medical services) OR (emergency AND medical AND services) OR (emergency medical services) OR (Warfare) OR (combat)) AND ((blood transfusion) OR (blood AND transfusion))). Titles and abstracts were screened by two reviewers, and the full texts of all potentially eligible articles were retrieved.

All manuscripts discussing PHTRBC were eligible for inclusion, provided they were written in English, German, French or Dutch. Since we sought to describe typical practice and identify commonly used indications and transfusion triggers, we did not limit the inclusion to studies allowing comparisons between PHTRBC patients and controls. Reviews and editorials were excluded. Eligibility was assessed independently in a blinded manner by two reviewers (ET & SB). Disagreements about manuscript eligibility were resolved by discussion within the investigator group. Reference lists of suitable articles were screened for additional relevant content.

2.2. *Data abstraction* {#tme12667-sec-0009}
-----------------------

We developed a standardised data‐extraction sheet, which was refined after testing with the first 20 articles. In one case, further information was obtained after contacting the authors.[27](#tme12667-bib-0027){ref-type="ref"} The setting and type of transport the EMS used (civilian or military, scene or interfacility), as well as the availability, frequency and volume of PHTRBC transfusions were extracted. Descriptions of problems that arose during PHTRBC are summarised in the text.

Transfusion criteria were recorded and classified as "major criteria" or "minor criteria," depending on whether only one criterion needed to be met to initiate PHTRBC or whether a combination of several criteria was required. Some groups published studies regarding pre‐hospital transfusion with the same EMS more than once. In this case, only the most recent and best specified description of transfusion criteria was considered. Criteria are summarised in diagrams (Figures [2](#tme12667-fig-0002){ref-type="fig"} and [3](#tme12667-fig-0003){ref-type="fig"}).

3. RESULTS {#tme12667-sec-0010}
==========

3.1. *Selection of articles* {#tme12667-sec-0011}
----------------------------

The search in PubMed and Web of Science yielded 2172 hits after removal of duplicates. Of which, 2024 articles were excluded based on the title and/or abstract, because they did not discuss PHTRBC or were not original research (eg, editorials, reviews). Ninety articles were excluded after screening their full texts because they did not meet the inclusion criteria. For this review, 71 articles were included (Figure [1](#tme12667-fig-0001){ref-type="fig"}).

![PRISMA flow diagram](TME-30-86-g001){#tme12667-fig-0001}

In total, 57 articles discussed PHTRBC in civilian medical services. Notably, five articles primarily dealt with a different study topic, but were included as they additionally provided valuable information regarding PHTRBC.[28](#tme12667-bib-0028){ref-type="ref"}, [29](#tme12667-bib-0029){ref-type="ref"}, [30](#tme12667-bib-0030){ref-type="ref"}, [31](#tme12667-bib-0031){ref-type="ref"}, [32](#tme12667-bib-0032){ref-type="ref"} Table [1](#tme12667-tbl-0001){ref-type="table"} describes studies\' characteristics, listing study design, region and period in which the study took place, the primary goal, study group and control group, whether matching occurred, the number of subjects, the type of transport and, in the case of trauma patients, the mechanism of injury and Injury Severity Score.

###### 

Overview of studies

<table><thead><tr class="header"><th style="text-align: left;">References</th><th style="text-align: left;">Region</th><th style="text-align: left;">Study period</th><th style="text-align: left;">Primary goal</th><th style="text-align: left;">Study group</th><th style="text-align: left;">Control group</th><th style="text-align: left;">Control for confounding</th><th style="text-align: left;">Patients transfused (n)<a href="#tme12667-note-0003" data-ref-type="fn">a</a></th><th style="text-align: left;">Type of transport (%trauma)</th><th style="text-align: left;">Mechanism of injury</th><th style="text-align: left;">ISS</th></tr></thead><tbody><tr class="odd"><td style="text-align: left;"><em>Civilian services</em></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Prospective comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Henriksen<a href="#tme12667-bib-0066" data-ref-type="ref">66</a></td><td style="text-align: left;">Texas, United States</td><td style="text-align: left;">2012‐2013</td><td style="text-align: left;">To investigate the association between PHTRBC and PHT‐plasma and haemostatic function</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">Receivers of in‐hospital transfusion</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">75<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHT: Blunt: 55%</p><p>Penetrating: 45%</p><p>Control: Blunt: 75%</p><p>Penetrating: 25% <em>P</em> = .002</p></td><td style="text-align: left;"><p>PHT: 29 (17‐41)</p><p>Control: 26 (17‐34) <em>P</em> = .106</p></td></tr><tr class="even"><td style="text-align: left;">Holcomb<a href="#tme12667-bib-0052" data-ref-type="ref">52</a></td><td style="text-align: left;">United States (9 trauma centres)</td><td style="text-align: left;">2015</td><td style="text-align: left;">To study the effect of PHTRBC and/or PHT‐plasma on in‐hospital mortality</td><td style="text-align: left;">Severely injured receivers of PHTRBC and/or plasma</td><td style="text-align: left;">No pre‐hospital blood products</td><td style="text-align: left;">Propensity score</td><td style="text-align: left;">142<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHT: Blunt: 79.1%</p><p>Penetrating: 20.9%</p><p>Matched control: Blunt: 72.7%</p><p>Penetrating: 27.3%</p></td><td style="text-align: left;"><p>PHT: 24 (10‐34)</p><p>Control: 22 (10‐34)</p></td></tr><tr class="odd"><td style="text-align: left;">Smith<a href="#tme12667-bib-0082" data-ref-type="ref">82</a></td><td style="text-align: left;">Midlands East of England, United Kingdom</td><td style="text-align: left;">2016‐2020</td><td style="text-align: left;">Study protocol for RCT: to investigate the effect of PHTRBC and PHT‐plasma on tissue perfusion and mortality</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">Receivers of crystalloids</td><td style="text-align: left;">RCT</td><td style="text-align: left;">Plan: 490</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Retrospective comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Brown<a href="#tme12667-bib-0048" data-ref-type="ref">48</a></td><td style="text-align: left;">United States (9 institutions)</td><td style="text-align: left;">2003‐2010</td><td style="text-align: left;">To characterise the association of pre‐trauma centre RBC with mortality and TIC in severely injured patients with blunt trauma</td><td style="text-align: left;">Receivers of pre‐trauma centre RBC</td><td style="text-align: left;">No pre‐hospital transfusion</td><td style="text-align: left;">Propensity score</td><td style="text-align: left;">50</td><td style="text-align: left;">Scene+ interfacility (100%)</td><td style="text-align: left;"><p>Blunt: 100%</p><p>Penetrating: 0% (per exclusion)</p></td><td style="text-align: left;"><p>PHTRBC: 34 (18‐43)</p><p>Control: 30 (23‐43) <em>P</em> = .81</p></td></tr><tr class="even"><td style="text-align: left;">Brown<a href="#tme12667-bib-0049" data-ref-type="ref">49</a></td><td style="text-align: left;">Pennsylvania, United States</td><td style="text-align: left;">2007‐2012</td><td style="text-align: left;">To evaluate the association of pre‐trauma centre RBC with outcomes</td><td style="text-align: left;">Receivers of pre‐trauma centre RBC</td><td style="text-align: left;">No pre‐hospital transfusion</td><td style="text-align: left;">Propensity score</td><td style="text-align: left;">240 matched (71 scene)</td><td style="text-align: left;">Scene+ interfacility (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 191 (80%)</p><p>Penetrating: 49 (20%)</p><p>Matched controls: Blunt: 395 (82%)</p><p>Penetrating: 85 (18%)</p></td><td style="text-align: left;"><p>PHTRBC:</p><p>18 (10‐29)</p><p>Matched control: 17 (9–27) <em>P</em> = .05</p></td></tr><tr class="odd"><td style="text-align: left;">Griggs<a href="#tme12667-bib-0069" data-ref-type="ref">69</a></td><td style="text-align: left;">Kent, Surrey and Sussex, United Kingdom</td><td style="text-align: left;">2010‐2015</td><td style="text-align: left;">To compare mortality for patients with suspected traumatic haemorrhage receiving PHTRBC compared with crystalloid</td><td style="text-align: left;">Code Red patients receiving PHTRBC</td><td style="text-align: left;">Code Red patients receiving crystalloids</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">92</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 95% Penetrating: 5% MVC 68% Fall 9% Control: Blunt: 99% Penetrating: 1% MVC: 58% Fall: 9%</p></td><td style="text-align: left;"><p>Mean (SD) PHTRBC:32 (12) Control: 21 (14) <em>P</em> = .67</p></td></tr><tr class="even"><td style="text-align: left;">Holcomb<a href="#tme12667-bib-0025" data-ref-type="ref">25</a></td><td style="text-align: left;">Texas, United States</td><td style="text-align: left;">2011‐2013</td><td style="text-align: left;">To evaluate the effect of PHTRBC and/or PHT‐plasma on survival and blood product use</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">Receivers of in‐hospital transfusion</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">137<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHT: Blunt: 77%</p><p>Penetrating: 23%</p><p>Control: Blunt 83%</p><p>Penetrating 17% <em>P</em> = .447</p></td><td style="text-align: left;"><p>PHT: 22 (12‐29)</p><p>Control: 22 (11‐33) <em>P</em> = .998</p></td></tr><tr class="odd"><td style="text-align: left;">Kim<a href="#tme12667-bib-0029" data-ref-type="ref">29</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2009‐2011</td><td style="text-align: left;">To analyse the effect of PHT‐plasma on coagulopathy</td><td style="text-align: left;">Receivers of PHT‐plasma + PHTRBC</td><td style="text-align: left;">Receivers of PHTRBC only</td><td style="text-align: left;">No</td><td style="text-align: left;">59 (of whom 50 RBC only)</td><td style="text-align: left;">Scene + interfacility (100%)</td><td style="text-align: left;"><p>Plasma: Blunt: 67% Penetrating: 33%</p><p>PHTRBC only: Blunt: 82%</p><p>Penetrating 18% <em>P</em> = .317</p></td><td style="text-align: left;"><p>Plasma: 27</p><p>PHTRBC: 23 <em>P</em> = .918</p></td></tr><tr class="even"><td style="text-align: left;">Miller<a href="#tme12667-bib-0050" data-ref-type="ref">50</a></td><td style="text-align: left;">Tennessee, United States</td><td style="text-align: left;">2007‐2013</td><td style="text-align: left;">To examine the impact of PHTRBC on mortality</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">No pre‐hospital transfusion</td><td style="text-align: left;">Propensity score</td><td style="text-align: left;">231 (195 matched)</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 78%</p><p>Penetrating: 22%</p><p>Matched control: Blunt: 90%</p><p>Penetrating: 10% <em>P</em> &lt; .001</p></td><td style="text-align: left;"><p>PHTRBC: 34 (22‐43)</p><p>Matched control: 32 (22‐43) <em>P</em> = .903</p></td></tr><tr class="odd"><td style="text-align: left;">Parker<a href="#tme12667-bib-0067" data-ref-type="ref">67</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2010‐2014</td><td style="text-align: left;">To examine PHT of plasma and/or RBC on outcomes in exsanguinating GI bleeding</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma with acute GI bleeding</td><td style="text-align: left;">Against GI‐bleed patients without transfusion</td><td style="text-align: left;">No</td><td style="text-align: left;">112<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Interfacility (0%)</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td></tr><tr class="even"><td style="text-align: left;">Peters<a href="#tme12667-bib-0074" data-ref-type="ref">74</a></td><td style="text-align: left;">Nijmegen and Rotterdam, The Netherlands</td><td style="text-align: left;">2007‐2015</td><td style="text-align: left;">To establish the efficacy and safety of the PHTRBC by HEMS</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">Receivers of crystalloids only</td><td style="text-align: left;">Matched</td><td style="text-align: left;">73 (50 matched)</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 93%</p><p>Penetrating: 7%</p><p>MVC 70%</p><p>Fall from height 10%</p><p>Matched control: Blunt: 94%</p><p>Penetrating: 6%</p><p>MVC 68%</p><p>Fall from height 12%</p></td><td style="text-align: left;"><p>PHTRBC: 34 (9‐75)</p><p>Control: 35 (18‐75) <em>P</em> = .242</p></td></tr><tr class="odd"><td style="text-align: left;">Price<a href="#tme12667-bib-0065" data-ref-type="ref">65</a></td><td style="text-align: left;">Oregon, United States</td><td style="text-align: left;">1989‐1995</td><td style="text-align: left;">To evaluate the efficacy of early blood transfusion</td><td style="text-align: left;">Receivers of PHTRBC during air transport</td><td style="text-align: left;">Receivers of crystalloids in ground transport</td><td style="text-align: left;">Matched</td><td style="text-align: left;">84</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Rehn<a href="#tme12667-bib-0063" data-ref-type="ref">63</a></td><td style="text-align: left;">London, United Kingdom</td><td style="text-align: left;">2009‐2015</td><td style="text-align: left;">To investigate the effect of PHTRBC on overall blood product use</td><td style="text-align: left;">“Code Red” patients after implementation of PHTRBC</td><td style="text-align: left;">“Code Red” patients before implementation of PHTRBC</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">128</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 64.8%</p><p>Penetrating: 35.2%</p><p>MVC: 42.2%</p><p>Falls: 11.7%</p><p>Control: Blunt: 68.6%</p><p>Penetrating: 31.4%</p><p>MVC: 42.3%</p><p>Falls: 12.4%</p><p>Other blunt: 13.9%</p></td><td style="text-align: left;"><p>PHTRBC: 29 (25‐43)</p><p>Control: 27 (19‐41)</p></td></tr><tr class="odd"><td style="text-align: left;">Rehn<a href="#tme12667-bib-0051" data-ref-type="ref">51</a></td><td style="text-align: left;">London, United Kingdom</td><td style="text-align: left;">2009‐2015</td><td style="text-align: left;">To investigate the effect of PHTRBC on mortality</td><td style="text-align: left;">“Code Red” patients after implementation of PHTRBC</td><td style="text-align: left;">“Code Red” patients before implementation of PHTRBC</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">239</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>PHTRBC: Blunt: 146 (61%)</p><p>Penetrating 93 (39%)</p><p>Control: Blunt: 189 (63%)</p><p>Penetrating: 111 (37%)</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Sumida<a href="#tme12667-bib-0073" data-ref-type="ref">73</a></td><td style="text-align: left;">Tennessee and Connecticut, United States</td><td style="text-align: left;">1995‐1996</td><td style="text-align: left;">To analyse the effect of PHTRBC on physiologic parameters and outcome</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">Receivers of crystalloids only</td><td style="text-align: left;">No</td><td style="text-align: left;">17</td><td style="text-align: left;">Scene + interfacility (100%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;"><p>PHTRBC 28</p><p>Control: 27.8</p><p><em>P</em> = .957</p></td></tr><tr class="odd"><td style="text-align: left;">Prospective not‐comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Chang<a href="#tme12667-bib-0032" data-ref-type="ref">32</a></td><td style="text-align: left;">United States (9 trauma centres)</td><td style="text-align: left;">2015</td><td style="text-align: left;">To describe the phenotype and laboratory coagulation abnormalities of clinically evident coagulopathic bleeding (CC) after trauma</td><td style="text-align: left;">Highest‐risk trauma patients, CC+</td><td style="text-align: left;">CC−</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">PHTRBC in CC+ vs CC− 18 (44%) vs 82 (8%) <em>P</em> &lt; .001</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>Overall: CC+ vs CC−: Blunt: 28 (68%) vs 792 (81%)</p><p>Penetrating: 12 (30%) vs 165 (17%)</p><p>Both: 1 (2%) vs 21 (2%)</p><p>Injury type <em>P</em> = .09</p></td><td style="text-align: left;"><p>CC+: 32 (25‐41)</p><p>CC−: 17 (8‐27)</p><p><em>P</em> &lt; .001</p></td></tr><tr class="odd"><td style="text-align: left;">Reed<a href="#tme12667-bib-0031" data-ref-type="ref">31</a></td><td style="text-align: left;">Scotland</td><td style="text-align: left;">2013‐2015</td><td style="text-align: left;">To evaluate the pre‐hospital activation of Code Red</td><td style="text-align: left;">Patients for whom a pre‐hospital Code Red was activated</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">16</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;"><p>Overall: Blunt: 44 (83%)</p><p>Penetrating: 9 (17%)</p></td><td style="text-align: left;">Overall: 24 (14‐37)</td></tr><tr class="even"><td style="text-align: left;">Sherren<a href="#tme12667-bib-0072" data-ref-type="ref">72</a></td><td style="text-align: left;">Greater Sydney Area, Australia</td><td style="text-align: left;">n/s (5 years.)</td><td style="text-align: left;">To describe PHTRBC</td><td style="text-align: left;">Missions involving PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">147</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;"><p>Blunt: 93.9%</p><p>Penetrating: 6.1%</p><p>MVC: 79</p><p>Fall from height: 3.4%</p><p>Other: 11.6%</p></td><td style="text-align: left;">RTS: 5.967 (4.083‐6.904)</td></tr><tr class="odd"><td style="text-align: left;">Tilney<a href="#tme12667-bib-0043" data-ref-type="ref">43</a></td><td style="text-align: left;">New England, United States</td><td style="text-align: left;">n/s (7 years.)</td><td style="text-align: left;">To examine utilisation, indications and outcomes in PHTRBC</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">179</td><td style="text-align: left;">Scene + interfacility (70%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Weaver<a href="#tme12667-bib-0071" data-ref-type="ref">71</a></td><td style="text-align: left;">London, United Kingdom</td><td style="text-align: left;">2012</td><td style="text-align: left;">To examine the impact of on‐scene PHTRBC for seriously injured patients</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">50</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Retrospective not‐comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Bamber<a href="#tme12667-bib-0060" data-ref-type="ref">60</a></td><td style="text-align: left;">East of England, United Kingdom</td><td style="text-align: left;">2013</td><td style="text-align: left;">To determine how blood was transferred with patients and the fate of this blood</td><td style="text-align: left;">RBCs and/or FFP transferred with patients</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">PHTRBC: 4</td><td style="text-align: left;">Interfacility (in PHTRBC 75%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Berns<a href="#tme12667-bib-0042" data-ref-type="ref">42</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">1993‐1996</td><td style="text-align: left;">To document the development of protocols for and to review the experience with PHTRBC</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">94</td><td style="text-align: left;">Scene + interfacility (48%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Bodnar<a href="#tme12667-bib-0068" data-ref-type="ref">68</a></td><td style="text-align: left;">Greater Brisbane, Australia</td><td style="text-align: left;">2011‐2012</td><td style="text-align: left;">To describe the characteristics, clinical interventions and the outcomes of PHTRBC patients</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">71</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>Blunt: 73.2%</p><p>Penetrating: 26.8%</p><p>MVC 67%</p></td><td style="text-align: left;">Mean (SD) 32.1 (18.2)</td></tr><tr class="odd"><td style="text-align: left;">Dalton<a href="#tme12667-bib-0064" data-ref-type="ref">64</a></td><td style="text-align: left;">Oregon Washington, United States</td><td style="text-align: left;">1985‐1992</td><td style="text-align: left;">To show that PHTRBC is safe and practical</td><td style="text-align: left;">Receivers of PHTRBC with MAST</td><td style="text-align: left;">Receivers of PHTRBC without MAST</td><td style="text-align: left;">n/a</td><td style="text-align: left;">112</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;"><p>Overall: Blunt: 86%</p><p>Penetrating: 14%</p><p>MVC: 72%</p></td><td style="text-align: left;"><p>Mean: MAST: 33</p><p>Non‐MAST: 31</p></td></tr><tr class="even"><td style="text-align: left;">Fahy<a href="#tme12667-bib-0053" data-ref-type="ref">53</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2002‐2014</td><td style="text-align: left;">To report our experience with a pre‐hospital transfusion protocol in paediatric patients</td><td style="text-align: left;">Paediatric trauma patients receiving PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">Paediatric non‐trauma patients receiving PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">n/a</td><td style="text-align: left;">28<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene+ interfacility (57%)</td><td style="text-align: left;"><p>Blunt: 88%</p><p>Penetrating: 12%</p><p>MVC: 63%</p><p>Gunshot wounds: 13%</p></td><td style="text-align: left;">24 (range 9‐66)</td></tr><tr class="odd"><td style="text-align: left;">Heschl<a href="#tme12667-bib-0061" data-ref-type="ref">61</a></td><td style="text-align: left;">Victoria, Australia</td><td style="text-align: left;">2011‐2015</td><td style="text-align: left;">To describe the characteristics of PHTRBC</td><td style="text-align: left;">All cases where approval for PHTRBC was sought by paramedics</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">142</td><td style="text-align: left;">Scene (96%)</td><td style="text-align: left;"><p>Blunt/penetrating: n/d</p><p>MVC: 88%</p><p>Crush/fall/other: 11.8%</p></td><td style="text-align: left;">Mean (SD): 36.5 (15.8)</td></tr><tr class="even"><td style="text-align: left;">Higgins<a href="#tme12667-bib-0045" data-ref-type="ref">45</a></td><td style="text-align: left;">Maine, United States</td><td style="text-align: left;">2007‐2008</td><td style="text-align: left;">To describe PHTRBC with respect to safety and efficacy and improvement in condition</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">45</td><td style="text-align: left;">Scene+ interfacility (71%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Hooper<a href="#tme12667-bib-0004" data-ref-type="ref">4</a></td><td style="text-align: left;">Southwest United Kingdom</td><td style="text-align: left;">2015‐2016</td><td style="text-align: left;">To describe experience with PHTRBC</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">62</td><td style="text-align: left;">n/d (84%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Krook<a href="#tme12667-bib-0044" data-ref-type="ref">44</a></td><td style="text-align: left;">Western Canada</td><td style="text-align: left;">2013‐2017</td><td style="text-align: left;">To describe the implementation and stewardship of a pre‐hospital blood transfusion programme</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">274</td><td style="text-align: left;">Scene + interfacility (74%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Krugh<a href="#tme12667-bib-0041" data-ref-type="ref">41</a></td><td style="text-align: left;">Ohio, United States</td><td style="text-align: left;">1991‐1993</td><td style="text-align: left;">To describe and review the implementation of an off‐site blood product storage programme</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">8</td><td style="text-align: left;">n/d (50%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Lyon<a href="#tme12667-bib-0070" data-ref-type="ref">70</a></td><td style="text-align: left;">Kent, Surrey and Sussex, United Kingdom</td><td style="text-align: left;">2013‐2014</td><td style="text-align: left;">To describe the characteristics of receivers of PHTRBC and evaluate their subsequent in‐hospital needs</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">147</td><td style="text-align: left;">Scene (97%)</td><td style="text-align: left;"><p>Blunt: 128 (87%)</p><p>Penetrating: 14 (10%)</p><p>MVC: 103 (73%)</p><p>Fall from height: 17 (11.6%)</p></td><td style="text-align: left;">33 (SD 13.4)</td></tr><tr class="odd"><td style="text-align: left;">Maher<a href="#tme12667-bib-0058" data-ref-type="ref">58</a></td><td style="text-align: left;">Washington, United States</td><td style="text-align: left;">2015</td><td style="text-align: left;">To describe the development of a HEMS transfusion programme</td><td style="text-align: left;">Receivers of PHTRBC or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;"><p>RBC 13</p><p>FFP 3</p></td><td style="text-align: left;">Scene + interfacility (85%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Mena‐Munoz<a href="#tme12667-bib-0046" data-ref-type="ref">46</a></td><td style="text-align: left;">Pennsylvania, Ohio, and Maryland, United States</td><td style="text-align: left;">2003‐2012</td><td style="text-align: left;">To characterise receivers of out of hospital transfusion of blood products (mostly RBCs and/or plasma) during critical care transport</td><td style="text-align: left;">Receivers of out of hospital blood products</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">1440<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene + interfacility (19%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Mix<a href="#tme12667-bib-0079" data-ref-type="ref">79</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2011–2015</td><td style="text-align: left;">To determine whether opportunities for blood product administration by ground ALS ambulances exist</td><td style="text-align: left;">Adult trauma patients with potential need for pre‐hospital blood administration</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">28</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>Blunt: 26 (93%)</p><p>Penetrating: 2 (7%)</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Moylan<a href="#tme12667-bib-0028" data-ref-type="ref">28</a></td><td style="text-align: left;">North Carolina, United States</td><td style="text-align: left;">1985</td><td style="text-align: left;">To analyse the effect of air vs ground inter‐hospital transport on survival</td><td style="text-align: left;">Patients with trauma scores ≤12 transported by helicopter</td><td style="text-align: left;">Patients with trauma scores ≤12 transported by ground</td><td style="text-align: left;">Matched</td><td style="text-align: left;">50</td><td style="text-align: left;">Scene + interfacility (100%)</td><td style="text-align: left;"><p>Ground: MVC/industrial accident: 76%</p><p>Assault: 24%</p><p>Air: MVC or industrial accident: 85%</p><p>Assault: 15%</p></td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Potter<a href="#tme12667-bib-0054" data-ref-type="ref">54</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2003–2012</td><td style="text-align: left;">To summarise our initial experience with PHTRBC and PHT‐plasma in paediatric trauma patients</td><td style="text-align: left;">Receivers (&lt; 18 years) of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">16<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene + interfacility (100%)</td><td style="text-align: left;"><p>Blunt: 87.5%</p><p>Penetrating: 12.5%</p></td><td style="text-align: left;">Mean 30 (range 9–66)</td></tr><tr class="even"><td style="text-align: left;">Powell</td><td style="text-align: left;">Ohio, United States</td><td style="text-align: left;">2010‐2013</td><td style="text-align: left;">To evaluate the influence of the time between injury and transfusion on outcome</td><td style="text-align: left;">Receivers of RBC within 24 hours of hospital arrival</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">31</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;"><p>Blunt: 94%</p><p>Penetrating: 6%</p></td><td style="text-align: left;">29 (range 2‐75)</td></tr><tr class="odd"><td style="text-align: left;">Raitt<a href="#tme12667-bib-0062" data-ref-type="ref">62</a></td><td style="text-align: left;">Thames Valley, United Kingdom</td><td style="text-align: left;">2014‐2016</td><td style="text-align: left;">To review the appropriateness of PHTRBC and to identify outcomes</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">Scene (95%)</td><td style="text-align: left;"><p>Blunt: 53 (84%)</p><p>Penetrating: 7 (11%)</p><p>MVC 42 (67%)</p><p>Fall 8 (13%)</p></td><td style="text-align: left;">ISS 34 (21‐43)</td></tr><tr class="even"><td style="text-align: left;">Sanci</td><td style="text-align: left;">Ontario, Canada</td><td style="text-align: left;">2013–2015</td><td style="text-align: left;">To review blood components transferred with patients from peripheral EDs to a trauma centre</td><td style="text-align: left;">Blood components received at a tertiary care trauma facility</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">RBC: 127 U in 144 patients</td><td style="text-align: left;">Interfacility (68%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Sunde</td><td style="text-align: left;">Bergen, Norway</td><td style="text-align: left;">2014</td><td style="text-align: left;">To describe our preliminary results after implementing PHTRBC and PHT‐plasma</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">4<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (75%)</td><td style="text-align: left;"><p>Blunt: 67%</p><p>Penetrating: 33%</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Thiels<a href="#tme12667-bib-0047" data-ref-type="ref">47</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2002‐2014</td><td style="text-align: left;">To report our experience with pre‐hospital blood product transfusion</td><td style="text-align: left;">Non‐trauma patients receiving PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">Trauma patients receiving PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">No</td><td style="text-align: left;">PHTRBC 654</td><td style="text-align: left;">Scene + interfacility (36%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Wheeler<a href="#tme12667-bib-0030" data-ref-type="ref">30</a></td><td style="text-align: left;">New England, United States</td><td style="text-align: left;">2005‐2009</td><td style="text-align: left;">To determine factors associated with hypothermia</td><td style="text-align: left;">Trauma patients transported by HEMS, hypothermic on arrival</td><td style="text-align: left;">Non‐hypothermic trauma patients, transported by HEMS</td><td style="text-align: left;">n/a</td><td style="text-align: left;">30</td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">Mean ± SD: Hypothermic: 26.07 ± 11.86 Non‐hypoth: 15.53 ± 11.39</td></tr><tr class="even"><td style="text-align: left;">Case reports</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Garner</td><td style="text-align: left;">Sydney, Australia</td><td style="text-align: left;">1997</td><td style="text-align: left;">Case report</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">n/a</td><td style="text-align: left;">1<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;">Blunt: 100%</td><td style="text-align: left;">43 (n = 1)</td></tr><tr class="even"><td style="text-align: left;">Lawton</td><td style="text-align: left;">Queensland, Australia</td><td style="text-align: left;">n/s</td><td style="text-align: left;">Case report</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">n/a</td><td style="text-align: left;">1<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">Scene (100%)</td><td style="text-align: left;">Blunt: 100%</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Macnab</td><td style="text-align: left;">British Columbia, Canada</td><td style="text-align: left;">1996</td><td style="text-align: left;">Case report</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">n/a</td><td style="text-align: left;">1</td><td style="text-align: left;">Interfacility (0%)</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td></tr><tr class="even"><td style="text-align: left;">Description of protocol</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Bodnar<a href="#tme12667-bib-0024" data-ref-type="ref">24</a></td><td style="text-align: left;">Greater Brisbane, Australia</td><td style="text-align: left;">2011–2012</td><td style="text-align: left;">To evaluate the feasibility, limitations and costs involved in PHTRBC</td><td style="text-align: left;">Review of a blood database</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Escott</td><td style="text-align: left;">Texas, United States</td><td style="text-align: left;">2016‐2017</td><td style="text-align: left;">To address the efficacy, risk and logistical challenges of PHT</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">23</td><td style="text-align: left;">n/d (20%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Jenkins<a href="#tme12667-bib-0059" data-ref-type="ref">59</a></td><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2008‐2010</td><td style="text-align: left;">To detail the development and implementation of novel programmes to care for haemorrhage patients requiring PHT</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">&gt;300</td><td style="text-align: left;">n/d (33%)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Lassale<a href="#tme12667-bib-0083" data-ref-type="ref">83</a></td><td style="text-align: left;">Provence‐Alpes‐Côte d'Azur, France</td><td style="text-align: left;">2010</td><td style="text-align: left;">To present a regional procedure for PHTRBC</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Trembley<a href="#tme12667-bib-0080" data-ref-type="ref">80</a></td><td style="text-align: left;">Minnesota Wisconsin, United States</td><td style="text-align: left;">2016</td><td style="text-align: left;">Description of implementation of protocol</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">Scene + interfacility (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Vartanian<a href="#tme12667-bib-0081" data-ref-type="ref">81</a></td><td style="text-align: left;">Texas, United States</td><td style="text-align: left;">2016</td><td style="text-align: left;">Description of implementation of protocol</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">12</td><td style="text-align: left;">n/d (67%)</td><td style="text-align: left;"><p>Blunt: 7 (87%)</p><p>Penetrating: 1 (12%)</p><p>MVC: 5 (62%)</p><p>Fall: 1 (8%)</p></td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Zielinski<a href="#tme12667-bib-0027" data-ref-type="ref">27</a></td><td style="text-align: left;">Norway</td><td style="text-align: left;">2016</td><td style="text-align: left;">To disseminate the lessons learned from trauma and haemostasis oxygenation research (THOR) network meeting</td><td style="text-align: left;">Description of PHTRBC in Norwegian HEMS</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">1–2%</td><td style="text-align: left;">Scene + interfacility (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Minnesota, United States</td><td style="text-align: left;">2016</td><td style="text-align: left;">Description of PHTRBC</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">Scene + interfacility (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Surveys/forum</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Gillon<a href="#tme12667-bib-0037" data-ref-type="ref">37</a></td><td style="text-align: left;">Western Australia</td><td style="text-align: left;">2009‐2010</td><td style="text-align: left;">Letter to editor. Mentions international analysis of major haemorrhage management by aeromedical services</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">none</td><td style="text-align: left;">n/a</td><td style="text-align: left;">58<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;"></td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Karl<a href="#tme12667-bib-0038" data-ref-type="ref">38</a></td><td style="text-align: left;">United States</td><td style="text-align: left;">2012</td><td style="text-align: left;">To characterise the blood‐carrying practices by HEMS programmes across the United States</td><td style="text-align: left;">Surveys to 261 US HEMS programmes</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Naumann<a href="#tme12667-bib-0039" data-ref-type="ref">39</a></td><td style="text-align: left;">United Kingdom</td><td style="text-align: left;">2011–2015</td><td style="text-align: left;">To determine how often and which pre‐hospital resuscitation fluids are delivered in the United Kingdom in hypotensive trauma</td><td style="text-align: left;">Patients with hypotensive trauma attended by a doctor in pre‐hospital setting</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">PHTRBC: 16; 1 of whom also PHT‐plasma</td><td style="text-align: left;">n/d (100%)</td><td style="text-align: left;"><p>Overall hypotensive trauma: Blunt: 654 (92.5%)</p><p>Penetrating: 53 (7.5%)</p><p>MVC: 453 (62%)</p><p>Fall: 92 (13%)</p><p>Amputation: 2 (0.3%)</p></td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Vardon<a href="#tme12667-bib-0036" data-ref-type="ref">36</a></td><td style="text-align: left;">France</td><td style="text-align: left;">2012–2013</td><td style="text-align: left;">To survey the means available in the 370 French SMUR for haemorrhagic situations</td><td style="text-align: left;">Survey by email and then phone with all French SMUR leaders</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d (n/d)</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Yazer<a href="#tme12667-bib-0040" data-ref-type="ref">40</a></td><td style="text-align: left;">Australia, Canada, Denmark, France, Germany, Israel, The Netherlands, New Zealand, United Kingdom and United States</td><td style="text-align: left;">2018</td><td style="text-align: left;">To discover how different centres around the world are using blood products and pharmaceuticals in the pre‐hospital setting</td><td style="text-align: left;">International forum</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;"><em>Military services</em></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Prospective comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Vitalis<a href="#tme12667-bib-0057" data-ref-type="ref">57</a></td><td style="text-align: left;">French Armed Forces, Sahel</td><td style="text-align: left;">2016–2017</td><td style="text-align: left;">To evaluate the practices of battlefield transfusion (RBCs, plasma, FWB)</td><td style="text-align: left;">Severely injured receivers of PHT‐RBC or ‐plasma or ‐FWB</td><td style="text-align: left;">No battlefield transfusion</td><td style="text-align: left;">No</td><td style="text-align: left;">7<a href="#tme12667-note-0004" data-ref-type="fn">b</a> (4 of whom RBC)</td><td style="text-align: left;">POI + Role 1</td><td style="text-align: left;"><p>Overall: Blunt: 1 (4%)</p><p>Penetrating: 27 (96%)</p><p>Explosion 16 (57%)</p><p>Active external haemorrhage 12 (43%)</p></td><td style="text-align: left;"><p>PHT: 45 (33‐52)</p><p>Control: 25 (16‐22) <em>P</em> = .01</p></td></tr><tr class="even"><td style="text-align: left;">Retrospective comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Howard<a href="#tme12667-bib-0035" data-ref-type="ref">35</a></td><td style="text-align: left;">US Military, Afghanistan</td><td style="text-align: left;">2001‐2014</td><td style="text-align: left;">To evaluate potential influences on KIA mortality</td><td style="text-align: left;">Casualties who needed and received PHT</td><td style="text-align: left;">Casualties who needed but did not receive PHT</td><td style="text-align: left;">Adjusted data</td><td style="text-align: left;">75<a href="#tme12667-note-0005" data-ref-type="fn">c</a></td><td style="text-align: left;">Pre‐hospital helicopter transport to FST or CSH</td><td style="text-align: left;"><p>Overall: Explosion: 65.1%</p><p>Gunshot: 22.5%</p><p>Blunt or other: 11.4%</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">O'Reilly<a href="#tme12667-bib-0055" data-ref-type="ref">55</a></td><td style="text-align: left;">UK MERT‐E, Afghanistan</td><td style="text-align: left;">2006‐2011</td><td style="text-align: left;">To evaluate the effect of PHTRBC/PHT‐plasma on mortality</td><td style="text-align: left;">Receivers of PHTRBC and PHT‐plasma</td><td style="text-align: left;">Matched patients where no PHT available</td><td style="text-align: left;">Propensity score</td><td style="text-align: left;">97<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI + Role 1</td><td style="text-align: left;"><p>PHT: Blunt: 1% Penetrating: 99%</p><p>Burn: 0%</p><p>Explosive: 51.5%</p><p>Gunshot wound: 47.4%</p><p>Matched control: Blunt: 3.1%</p><p>Penetrating: 96.9%</p><p>Burn: 0%</p><p>Explosive: 49.5%</p><p>Gunshot wound: 47.4%</p></td><td style="text-align: left;"><p>PHT:</p><p>16 (9–25) Control:</p><p>16 (9‐24.5) <em>P</em> = .686</p></td></tr><tr class="odd"><td style="text-align: left;">Shackelford<a href="#tme12667-bib-0078" data-ref-type="ref">78</a></td><td style="text-align: left;">UK MERT, US Air Force Pedro, US DUSTOFF, Afghanistan</td><td style="text-align: left;">2012‐2015</td><td style="text-align: left;">To examine the association of PHTRBC and/or PHT‐plasma and time to initial transfusion with injury survival</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">No PHT</td><td style="text-align: left;">Frequency matched</td><td style="text-align: left;">55<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI to role 2 or 3</td><td style="text-align: left;"><p>PHT: Explosives 84%</p><p>Gunshot wound 16%</p><p>≥1 amputation: 73%</p><p>Haemorrhagic torso injury 56%</p><p>Control: Explosives: 71%</p><p>Gunshot wound: 29% <em>P</em> = .05</p><p>≥1 amputation: 27% <em>P</em> &lt; .001</p><p>Haemorrhagic torso injury: 35% <em>P</em> = .004</p></td><td style="text-align: left;"><p>PHT: 29 (17–36)</p><p>Control: 28.6 (24.0‐33.2) <em>P</em> = .88</p></td></tr><tr class="even"><td style="text-align: left;">Prospective not‐comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Aye Maung<a href="#tme12667-bib-0077" data-ref-type="ref">77</a></td><td style="text-align: left;">UK Army, Afghanistan</td><td style="text-align: left;">2012‐2014</td><td style="text-align: left;">To explore the utility and feasibility of forward transfusion of RBC</td><td style="text-align: left;">Missions where blood components were carried</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">2</td><td style="text-align: left;">POI + role 1</td><td style="text-align: left;">Gunshot wound: 100% (n = 2)</td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Malsby</td><td style="text-align: left;">US Army, Afghanistan</td><td style="text-align: left;">2012</td><td style="text-align: left;">Process improvement initiative of blood product transfusion on urgent helicopter evacuation casualties</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">15<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI + Role 1</td><td style="text-align: left;"><p>Explosion: 87%</p><p>Gunshot wound: 13%</p><p>≥1 amputation: 60%</p></td><td style="text-align: left;">n/d</td></tr><tr class="odd"><td style="text-align: left;">Retrospective not‐comparative studies</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Barkana<a href="#tme12667-bib-0076" data-ref-type="ref">76</a></td><td style="text-align: left;">Israel Defense Force Medical Corps, Israel</td><td style="text-align: left;">1994‐1996</td><td style="text-align: left;">To characterise the different aspects of PHTRBC and to evaluate its potential effect on the morbidity and mortality</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">40</td><td style="text-align: left;">POI + role 1</td><td style="text-align: left;"><p>Blunt: 22.5%</p><p>Penetrating: 77.5%</p><p>Explosion: 47.5%</p><p>Gunshot wounds: 22.5%</p><p>Explosion + gunshot wounds: 7.5%</p><p>MVC: 20%</p><p>Fall from height: 2.5%</p></td><td style="text-align: left;">18 (11.5‐25)</td></tr><tr class="odd"><td style="text-align: left;">Chen<a href="#tme12667-bib-0056" data-ref-type="ref">56</a></td><td style="text-align: left;">Israeli Air Force, Israel</td><td style="text-align: left;">2003–2010</td><td style="text-align: left;">To describe PHTRBC, and to evaluate adherence to clinical practice guidelines</td><td style="text-align: left;">Receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">89</td><td style="text-align: left;">Scene + interfacility</td><td style="text-align: left;"><p>Combat: 69% Non‐combat: 31%</p><p>Gunshot wounds: 36%</p><p>MVC: 28%</p><p>Explosions: 24%</p><p>Stab wound: 4%</p><p>Plane crash: 2%</p><p>Fall from height: 2%</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Edgar<a href="#tme12667-bib-0034" data-ref-type="ref">34</a></td><td style="text-align: left;">US and UK Military, Afghanistan</td><td style="text-align: left;">2011</td><td style="text-align: left;">To compare initial management and early outcomes in patients suffering bilateral lower limb amputations and differences related to the type of aeromedical evacuation assets</td><td style="text-align: left;">Surviving adult male patients with bilateral traumatic lower limb amputations transferred by MERT in a CH‐47 Chinook helicopter</td><td style="text-align: left;">Against those transferred by PEDRO in an HH‐60 Pavehawk helicopter</td><td style="text-align: left;">n/a</td><td style="text-align: left;">n/d</td><td style="text-align: left;"><p>POI to</p><p>Role 3</p></td><td style="text-align: left;">Only patients with bilateral lower limb amputations</td><td style="text-align: left;"><p>NISS</p><p>MERT: 27 (range 19–41)</p><p>PEDRO: 27 (range 22‐29) <em>P</em> = 1</p></td></tr><tr class="odd"><td style="text-align: left;">Morrison<a href="#tme12667-bib-0033" data-ref-type="ref">33</a></td><td style="text-align: left;">US and UK Military, Afghanistan</td><td style="text-align: left;">2008–2011</td><td style="text-align: left;">To characterise and compare mortality among casualties evacuated with conventional military retrieval (CMR) to those evacuated with an advanced medical retrieval (AMR) capability</td><td style="text-align: left;">Casualties evacuated from POI by an AMR capability</td><td style="text-align: left;">Against those evacuated by a medic‐led CMR capability</td><td style="text-align: left;">n/a</td><td style="text-align: left;">162<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI to role 3</td><td style="text-align: left;"><p>AMR: Blast: 70.4%</p><p>Gunshot: 24.3%</p><p>Other: 5.3%</p><p>CMR: Blast: 60.8% <em>P</em> &lt; .001</p><p>Gunshot: 34.9%</p><p>Other: 4.3%</p></td><td style="text-align: left;"><p>Mean (SD): AMR: 16 (17)</p><p>CMR: 15 (16) <em>P</em> = .122</p></td></tr><tr class="even"><td style="text-align: left;">O'Reilly<a href="#tme12667-bib-0055" data-ref-type="ref">55</a></td><td style="text-align: left;">UK MERT‐E, Afghanistan</td><td style="text-align: left;">2008–2011</td><td style="text-align: left;">To present the initial experience of military PHTRBC and PHT‐plasma</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">310<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI to role 2 or 3</td><td style="text-align: left;"><p>Blunt: 1.0%</p><p>Penetrating: 99%</p><p>Burn: 0.3%</p><p>Explosive: 72.9%</p><p>Gunshot wound 25.8%</p></td><td style="text-align: left;">20 (16‐29)</td></tr><tr class="odd"><td style="text-align: left;">Powell‐Dunford<a href="#tme12667-bib-0075" data-ref-type="ref">75</a></td><td style="text-align: left;">US Army, Afghanistan</td><td style="text-align: left;">2012</td><td style="text-align: left;">To enumerate the specific risks and risk management strategies of en route transfusion</td><td style="text-align: left;">Receivers of PHTRBC and/or PHT‐plasma</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">61<a href="#tme12667-note-0004" data-ref-type="fn">b</a> (54 of whom RBC)</td><td style="text-align: left;">n/d</td><td style="text-align: left;"><p>Explosion: 74%</p><p>Gunshot wound 26%</p></td><td style="text-align: left;">n/d</td></tr><tr class="even"><td style="text-align: left;">Shlaifer<a href="#tme12667-bib-0089" data-ref-type="ref">89</a></td><td style="text-align: left;">Israeli Defense Forces, Israel</td><td style="text-align: left;">2013‐2016</td><td style="text-align: left;">To describe feasibility, safety, adverse reactions and adherence to clinical practice guidelines in PHT‐plasma</td><td style="text-align: left;">Receivers of PHT‐plasma. Among them 9 receivers of PHTRBC</td><td style="text-align: left;">None</td><td style="text-align: left;">n/a</td><td style="text-align: left;">9<a href="#tme12667-note-0004" data-ref-type="fn">b</a></td><td style="text-align: left;">POI + Role 1</td><td style="text-align: left;"><p>Penetrating: 68.5%</p><p>Blunt: 15.2%</p><p>Burn: 1.1%</p><p>Blast: 1.1%</p><p>Combination: 14.1%</p></td><td style="text-align: left;">ISS 1–8:10.9% ISS 9‐14:20.7% ISS 16‐24:28.3% 25‐75:40.1%</td></tr><tr class="odd"><td style="text-align: left;">Case reports</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">West<a href="#tme12667-bib-0090" data-ref-type="ref">90</a></td><td style="text-align: left;">US Army, Afghanistan</td><td style="text-align: left;">2004</td><td style="text-align: left;">Case report</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">n/a</td><td style="text-align: left;">1</td><td style="text-align: left;">POI to FST</td><td style="text-align: left;">Penetrating: 100% (n = 1)</td><td style="text-align: left;">n/d</td></tr></tbody></table>

*Note:* Median (IQR) unless otherwise specified.

Abbreviations: AMR, advanced medical retrieval; CC, clinically evident coagulopathic bleeding; CMR, conventional military retrieval; CSH, Combat Support Hospital; FFP, fresh‐frozen plasma; FST, forward surgical team; FWB, fresh whole blood; GI, gastrointestinal; HEMS, Helicopter Emergency Medical Service; ISS, Injury Severity Score; KIA, killed in action; MAST, medical antishock trousers; MERT(−E): Medical Emergency Response Team (−enhanced); MVC, motor vehicle collision; n/a, not applicable; n/d, not described; n/s, not specified for PHTRBC; (N)ISS, (New) Injury Severity Score; PHT, pre‐hospital transfusion; PHTRBC, pre‐hospital transfusion of red blood cells; PHT‐plasma, pre‐hospital transfusion of plasma; POI, point of injury; RBCs, red blood cells; RCT, randomised clinical trial; RTS, revised trauma score; SMUR, Service Mobile d\'Urgence et Reanimation (Mobile Emergency and Resuscitation Service); TIC, trauma‐induced coagulopathy; U, Units.

PHTRBC unless otherwise specified; matched number of patients if applicable.

PHTRBC and/or other pre‐hospital blood component products.

Blood products not specified.

We included 14 articles discussing PHTRBC in military medical services. Three articles reported pre‐hospital transfusion as an additional topic, while primarily discussing another aspect of their study[33](#tme12667-bib-0033){ref-type="ref"}, [34](#tme12667-bib-0034){ref-type="ref"}, [35](#tme12667-bib-0035){ref-type="ref"} (Table [1](#tme12667-tbl-0001){ref-type="table"}).

3.2. *Availability of PHTRBC in civilian services* {#tme12667-sec-0012}
--------------------------------------------------

Four articles report surveys on the availability of pre‐hospital transfusion to civilian EMS. In France, 84% of 150 responding Mobile Emergency and Resuscitation Services were able to transfuse their patients with RBCs during the mission. However, the survey did not specify whether teams carried the blood products themselves, or had to order them to be delivered to the scene of injury.[36](#tme12667-bib-0036){ref-type="ref"} Gillon[37](#tme12667-bib-0037){ref-type="ref"} describes the Australian responses to an international survey of aeromedical services. Three out of seven services had immediate access to PHTRBC; the other four needed 45 minutes in order to obtain it. Karl et al[38](#tme12667-bib-0038){ref-type="ref"} report that 25.3% of 235 US Helicopter Emergency Medical Service (HEMS) programmes that responded to a survey carried blood, while a 2016 survey found that 10 out of the 22 HEMS in the United Kingdom carried blood products.[39](#tme12667-bib-0039){ref-type="ref"}

An international forum held in 2018 revealed that PHTRBC is practised in Australia, Canada, Denmark, France, Israel, the Netherlands, the United Kingdom, and the United States, and experience with this practice varied from \<7 years up to 35 years.[40](#tme12667-bib-0040){ref-type="ref"} The type of packed cells varied; five out of eight sites provide only O**−** RBCs, two provide only O+ RBCs, and one provides both O+ and O**−** RBCs. One site did not use leuco‐reduced RBCs, and one site used cytomegalovirus‐negative RBCs.

3.3. *Frequency of pre‐hospital transfusions* {#tme12667-sec-0013}
---------------------------------------------

For civilian EMS that transfuse blood prior to hospital arrival, their overall pre‐hospital transfusion rates vary from 0.2 to 4.4% of patients,[27](#tme12667-bib-0027){ref-type="ref"}, [41](#tme12667-bib-0041){ref-type="ref"}, [42](#tme12667-bib-0042){ref-type="ref"}, [43](#tme12667-bib-0043){ref-type="ref"}, [44](#tme12667-bib-0044){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [46](#tme12667-bib-0046){ref-type="ref"}, [47](#tme12667-bib-0047){ref-type="ref"} without evident differences between interfacility transport and primary transport from the scene (0.7‐6.2%[37](#tme12667-bib-0037){ref-type="ref"}, [38](#tme12667-bib-0038){ref-type="ref"} vs 4.9[38](#tme12667-bib-0038){ref-type="ref"}). For the overall population of trauma patients, transfusion rates ranging from 3.0% to 3.5% were reported[48](#tme12667-bib-0048){ref-type="ref"}, [49](#tme12667-bib-0049){ref-type="ref"} with transfusion occurring in 1.6% to 7.5% of trauma scene transports[48](#tme12667-bib-0048){ref-type="ref"}, [49](#tme12667-bib-0049){ref-type="ref"}, [50](#tme12667-bib-0050){ref-type="ref"}, [51](#tme12667-bib-0051){ref-type="ref"} and in 4.8% to 30% of interfacility transports.[48](#tme12667-bib-0048){ref-type="ref"}, [49](#tme12667-bib-0049){ref-type="ref"} Cohorts with more severely injured patients (median ISS 22,[25](#tme12667-bib-0025){ref-type="ref"} trauma score \< 12[28](#tme12667-bib-0028){ref-type="ref"} or "highest risk population"[52](#tme12667-bib-0052){ref-type="ref"}) report transfusions being performed for 19% to 24% of patients.[25](#tme12667-bib-0025){ref-type="ref"}, [28](#tme12667-bib-0028){ref-type="ref"}, [52](#tme12667-bib-0052){ref-type="ref"} In two articles reporting on paediatric patients only, the incidence of transfusion was 28 per 3957 (0.7%) transports,[53](#tme12667-bib-0053){ref-type="ref"} and of 1176 trauma patients, 16 (1.4%) were transfused.[54](#tme12667-bib-0054){ref-type="ref"}

In military services, pre‐hospital transfusion rates for trauma are markedly higher compiling all patients in civilian EMS, ranging from 14.8% to 26.9% of transports with blood available.[33](#tme12667-bib-0033){ref-type="ref"}, [55](#tme12667-bib-0055){ref-type="ref"}, [56](#tme12667-bib-0056){ref-type="ref"} With regard to only severely injured patients (ISS ≥51[33](#tme12667-bib-0033){ref-type="ref"} or patient "category alpha"[57](#tme12667-bib-0057){ref-type="ref"}), data are more comparable to the civilian setting, that is, 25% to 32% of more severely injured patients were transfused[33](#tme12667-bib-0033){ref-type="ref"}, [57](#tme12667-bib-0057){ref-type="ref"} vs 19% to 24% in the civilian setting.

3.4. *Number of units transfused* {#tme12667-sec-0014}
---------------------------------

In patients treated by a civilian EMS, 5 studies reported a mean/median of 1 unit transfused,[25](#tme12667-bib-0025){ref-type="ref"}, [29](#tme12667-bib-0029){ref-type="ref"}, [48](#tme12667-bib-0048){ref-type="ref"}, [52](#tme12667-bib-0052){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"} 17 studies report a mean/median of 1.1 to 2 units (or between 280 and 560 mL)[37](#tme12667-bib-0037){ref-type="ref"}, [41](#tme12667-bib-0041){ref-type="ref"}, [44](#tme12667-bib-0044){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [47](#tme12667-bib-0047){ref-type="ref"}, [49](#tme12667-bib-0049){ref-type="ref"}, [51](#tme12667-bib-0051){ref-type="ref"}, [59](#tme12667-bib-0059){ref-type="ref"}, [60](#tme12667-bib-0060){ref-type="ref"}, [61](#tme12667-bib-0061){ref-type="ref"}, [62](#tme12667-bib-0062){ref-type="ref"}, [63](#tme12667-bib-0063){ref-type="ref"}, [64](#tme12667-bib-0064){ref-type="ref"}, [65](#tme12667-bib-0065){ref-type="ref"}, [66](#tme12667-bib-0066){ref-type="ref"}, [67](#tme12667-bib-0067){ref-type="ref"}, [68](#tme12667-bib-0068){ref-type="ref"} and 8 studies reported a mean/median of 2.3 to 3 units transfused (or between 560 and 840 mL).[29](#tme12667-bib-0029){ref-type="ref"}, [31](#tme12667-bib-0031){ref-type="ref"}, [69](#tme12667-bib-0069){ref-type="ref"}, [70](#tme12667-bib-0070){ref-type="ref"}, [71](#tme12667-bib-0071){ref-type="ref"}, [72](#tme12667-bib-0072){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"}, [74](#tme12667-bib-0074){ref-type="ref"} Paediatric patients received a mean of 9.8 mL/kg[53](#tme12667-bib-0053){ref-type="ref"} or 255 mL (8 mL/kg).[54](#tme12667-bib-0054){ref-type="ref"}

In patients treated by a military EMS, most studies (6) reported a mean or median number of PHTRBC transfused of 0.9 to 1,[55](#tme12667-bib-0055){ref-type="ref"}, [57](#tme12667-bib-0057){ref-type="ref"}, [75](#tme12667-bib-0075){ref-type="ref"}, [76](#tme12667-bib-0076){ref-type="ref"}, [77](#tme12667-bib-0077){ref-type="ref"}, [78](#tme12667-bib-0078){ref-type="ref"} one study reported a median of 450 mL[56](#tme12667-bib-0056){ref-type="ref"} and one study reported transfusion of a median of 4 U of RBCs.[34](#tme12667-bib-0034){ref-type="ref"}

3.5. *Transfusion criteria in civilian services* {#tme12667-sec-0015}
------------------------------------------------

Figure [2](#tme12667-fig-0002){ref-type="fig"} shows the most common criteria for PHTRBC in adults by civilian services as reported by 20 unique groups. The most commonly reported criteria are follows: hypotension, tachycardia, clinical signs of poor perfusion, type of injury (ie, ongoing bleeding or penetrating wounds) or a clinician\'s judgement.[25](#tme12667-bib-0025){ref-type="ref"}, [27](#tme12667-bib-0027){ref-type="ref"}, [30](#tme12667-bib-0030){ref-type="ref"}, [41](#tme12667-bib-0041){ref-type="ref"}, [43](#tme12667-bib-0043){ref-type="ref"}, [44](#tme12667-bib-0044){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [46](#tme12667-bib-0046){ref-type="ref"}, [50](#tme12667-bib-0050){ref-type="ref"}, [51](#tme12667-bib-0051){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"}, [61](#tme12667-bib-0061){ref-type="ref"}, [64](#tme12667-bib-0064){ref-type="ref"}, [68](#tme12667-bib-0068){ref-type="ref"}, [70](#tme12667-bib-0070){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"}, [79](#tme12667-bib-0079){ref-type="ref"}, [80](#tme12667-bib-0080){ref-type="ref"}, [81](#tme12667-bib-0081){ref-type="ref"}, [82](#tme12667-bib-0082){ref-type="ref"} Not all groups explained their definition of "hypotension" or described which clinical signs were considered to indicate a state of poor perfusion. In Figure [2](#tme12667-fig-0002){ref-type="fig"}, these groups have been summarised in the sections "Hypotension---no cut‐off point provided", and "Clinical signs of poor perfusion---not further specified." In services where clinicians were explicitly allowed to initiate transfusion based on their clinical judgement, regardless of whether other criteria were met, this is summarised under "Clinician\'s judgement."

![Criteria for pre‐hospital transfusion of red blood cells (PHTRBC) most commonly used in civilian emergency medical services, and injury characteristics used as criteria for PHTRBC in civilian emergency medical services](TME-30-86-g002){#tme12667-fig-0002}

Some groups used laboratory or point‐of‐care test (POCT) results to aid in making the decision to transfuse (lactate ≥4 mmol/L[46](#tme12667-bib-0046){ref-type="ref"} or ≥5 mg/dL, INR ≥1.5, base deficit ≥5 mmol/L[79](#tme12667-bib-0079){ref-type="ref"} or Hb (cut‐off point \<9 g/dL, \<8 g/dL or \< 7 g/dL depending on symptoms and comorbidity.[44](#tme12667-bib-0044){ref-type="ref"}, [80](#tme12667-bib-0080){ref-type="ref"} For two groups, ultrasound contributed to decision making (one major, one minor criterion).[25](#tme12667-bib-0025){ref-type="ref"}, [70](#tme12667-bib-0070){ref-type="ref"} Furthermore, one group used tissue oxygen saturation (StO~2~) of ≤65% as an indication to transfuse (minor criterion).[79](#tme12667-bib-0079){ref-type="ref"}

In the case of interfacility transport, three groups explained that they would continue a transfusion started by the referring hospital (a major criterion),[43](#tme12667-bib-0043){ref-type="ref"}, [46](#tme12667-bib-0046){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"} and one group used a haemoglobin concentration reported by the referring hospital as a transfusion trigger (also a major criterion).[73](#tme12667-bib-0073){ref-type="ref"} Interestingly, 10 groups required the administration of crystalloids before their criteria would prompt transfusion.[30](#tme12667-bib-0030){ref-type="ref"}, [41](#tme12667-bib-0041){ref-type="ref"}, [43](#tme12667-bib-0043){ref-type="ref"}, [44](#tme12667-bib-0044){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"}, [61](#tme12667-bib-0061){ref-type="ref"}, [64](#tme12667-bib-0064){ref-type="ref"}, [70](#tme12667-bib-0070){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"}

3.6. *Transfusion criteria for paediatric patients in civilian services* {#tme12667-sec-0016}
------------------------------------------------------------------------

The criteria used for PHTRBC in children were described by seven groups. Six of these required signs of hypoperfusion to persist after other fluids were administered.[41](#tme12667-bib-0041){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [53](#tme12667-bib-0053){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"}, [81](#tme12667-bib-0081){ref-type="ref"} Five groups specified the required amount as 1 to 3 times 20 to 30 mL/kg of crystalloids before commencing RBCs; Fahy et al had the alternative option of starting with 10 mL/kg of plasma.[53](#tme12667-bib-0053){ref-type="ref"} The signs of hypoperfusion were described differently in each study: four groups looked at age‐appropriate hypotension,[41](#tme12667-bib-0041){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"}, [73](#tme12667-bib-0073){ref-type="ref"}, [81](#tme12667-bib-0081){ref-type="ref"} two groups also examined tachycardia,[45](#tme12667-bib-0045){ref-type="ref"}, [81](#tme12667-bib-0081){ref-type="ref"} three groups at "clinical signs of shock"[41](#tme12667-bib-0041){ref-type="ref"}, [45](#tme12667-bib-0045){ref-type="ref"}, [53](#tme12667-bib-0053){ref-type="ref"} and one group transfused if there was only a central pulse.[51](#tme12667-bib-0051){ref-type="ref"} Additionally, three groups allowed a clinician\'s judgement to supersede protocol.[41](#tme12667-bib-0041){ref-type="ref"}, [53](#tme12667-bib-0053){ref-type="ref"}, [58](#tme12667-bib-0058){ref-type="ref"}

3.7. *Transfusion criteria in military services* {#tme12667-sec-0017}
------------------------------------------------

Articles were available about pre‐hospital transfusion practices of the armed forces of France, Israel, the United Kingdom and the United States. Only the most recent description of transfusion criteria was included.[35](#tme12667-bib-0035){ref-type="ref"}, [55](#tme12667-bib-0055){ref-type="ref"}, [56](#tme12667-bib-0056){ref-type="ref"}, [57](#tme12667-bib-0057){ref-type="ref"}

Systolic blood pressure (SBP) \<90 mmHg is most often used as the cut‐off point in hypotension, while there is no consensus regarding the cut‐off point for tachycardia (\>100/min and \>120/min, respectively). The type of injury considered indicative of requiring a transfusion differs; obvious bleeding, proximal amputation or penetrating wounds are used as the criteria for instigation. Unlike the civilian services, only one of the groups advises the use of other fluids before blood products, and none specifically allows a clinician\'s judgement to supersede protocol (Figure [3](#tme12667-fig-0003){ref-type="fig"}). Chen et al[56](#tme12667-bib-0056){ref-type="ref"} describe the criteria for paediatric patients in the military setting. If there was evidence of persistent "haemorrhagic shock" after 2 × 20 mL/kg of crystalloids, RBCs could then be transfused.

![Criteria for pre‐hospital transfusion of red blood cells (PHTRBC) most commonly used in military emergency medical services, and injury characteristics used as criteria for PHTRBC in military emergency medical services](TME-30-86-g003){#tme12667-fig-0003}

3.8. *Challenges of PHTRBC* {#tme12667-sec-0018}
---------------------------

Several studies report the difficulties encountered when introducing PHTRBC. In the survey by Karl et al, 5.8% of EMS programmes had discontinued their PHTRBC programme because of access limitations, problematic storage logistics, underutilisation and costs.[38](#tme12667-bib-0038){ref-type="ref"}

Besides requiring a safe transport of blood products, a system needs to be set up to ensure traceability, in cases in which the patient\'s identity in unknown. It is important that the casualty\'s blood is drawn for future cross typing prior to transfusion. To minimise wastage, the return of unused units needs to be arranged.[83](#tme12667-bib-0083){ref-type="ref"}

Blood products require a separate intravenous line, and especially in the case of short transport times, transfusion can be performed at the expense of the administration of drugs. Jenkins et al mentioned that for these reasons, after the introduction of pre‐hospital blood products in their service, less patients received tranexamic acid.[59](#tme12667-bib-0059){ref-type="ref"}

Services with a large geographical population and longer transport times have a higher transfusion rate.[45](#tme12667-bib-0045){ref-type="ref"} For such services, carrying pre‐hospital blood products may be more cost effective. However, evidence regarding cost effectiveness is lacking.

4. DISCUSSION {#tme12667-sec-0019}
=============

This scoping review identified several studies reporting on the implementation of PHTRBC programmes or pre‐hospital transfusion criteria.

Bleeding patients may require transfusion of RBCs to restore compromised tissue perfusion and oxygenation. Although hard evidence for the beneficial effects of pre‐hospital transfusion is lacking, such transfusions should theoretically improve outcomes in selected patients with substantial blood loss. On the other hand, unnecessary transfusion involves unnecessary risks[84](#tme12667-bib-0084){ref-type="ref"}, [85](#tme12667-bib-0085){ref-type="ref"}, [86](#tme12667-bib-0086){ref-type="ref"} and wastage of resources, in particular, of valuable O negative units. Careful selection of patients is therefore paramount.

Theoretically, the patients to benefit most from early transfusion would be the patients in profound haemorrhagic shock or with ongoing massive bleeding. In hospital, these patients would often trigger the use of a Massive Transfusion Protocol, where massive transfusion is classically defined as the use of 10 or more units of PRBC in the first 24 hours. Also for in‐hospital transfusion, predicting the need for (massive) transfusion has its challenges, and multiple scores have been developed to this end. Each of these scores has limitations, as most of them have been derived retrospectively, were validated in a single centre and may not be applicable to different patient populations; some of them depend on the availability of laboratory and/or ultrasound.[87](#tme12667-bib-0087){ref-type="ref"} Even more so, it is challenging to appropriately identify patients who require blood transfusions in the pre‐hospital setting, where resources are limited and larger amounts of blood are not readily available.

To the best of our knowledge, pre‐hospital transfusion criteria have not been previously reviewed. Our review does not allow hard conclusions on which patients benefit from PHTRBC. However, we gathered published criteria for PHTRBC that are internationally used. Our systematic review can be considered a cross‐section of current practice regarding indications to initiate PHTRBC. In the absence of evidence, expert opinion is currently the best that is available to guide pre‐hospital transfusion, and our review may aid clinicians to design or refine protocols regarding pre‐hospital transfusion. The protocol for the Amsterdam HEMS has been based on the results of this review, and it is shown in Figure [4](#tme12667-fig-0004){ref-type="fig"}.

![Protocol for the initiation of pre‐hospital transfusion of red blood cells, Helicopter Emergency Medical Service "Lifeliner 1," Amsterdam, the Netherlands](TME-30-86-g004){#tme12667-fig-0004}

Our review suggests that there is a broad consensus that hypotension (most often defined as a systolic blood pressure \< 90 mmHg), tachycardia (most often defined as a heart rate \> 120 beats/min), clinical signs of poor perfusion (in particular changes in mental status) and the type of injury (in particular suspected or confirmed ongoing haemorrhage) are important transfusion triggers in the civilian setting. Similar criteria were reported in military literature.

However, we believe that the decision to initiate or withhold transfusion should not only be based on "hard" criteria but should also involve the clinical judgement of pre‐hospital healthcare providers. For example, a heart rate \> 120/min may be a stress response to pain, and changes in mental status are may be due to traumatic brain injury rather than haemorrhage. Such cases should not automatically prompt a transfusion, rather clinical judgement is needed to assess whether transfusion is the most appropriate therapy. In fact, clinical judgement was frequently allowed to supersede the protocol in published literature, and we explicitly agree with this recommendation.

Furthermore, uniform transfusion criteria may ultimately not be optimal: a 20‐year‐old healthy patient is likely able to tolerate a degree of hypotension and tachycardia that an 85‐year‐old is not. Ideally, individual transfusion triggers should be researched. Although not broadly established yet, we suggest studying portable blood‐gas analysers to support well‐informed RBC‐transfusion decisions. Herein, blood‐gas analysis quantifies the markers of anaerobic metabolism during haemorrhage (eg, lactate, pH and base excess) and allows for tracking RBC‐transfusion effects, for example, by restoration of acid/base homeostasis or increase in haemoglobin concentration. In a recent study, we were able to demonstrate the feasibility of portable blood‐gas analysis in the pre‐hospital setting, including pre‐hospital RBC transfusion.[88](#tme12667-bib-0088){ref-type="ref"} However, further studies are required to study how portable blood‐gas analysis may support RBC‐transfusion decision making, for example, by establishing acid/base‐derived trigger values.

This scoping review also highlights several challenges in the implementation of PHTRBC. EMS operators planning to implement pre‐hospital transfusions need to beware of the pitfalls regarding storage and cooling logistics, return of unused units and traceability of blood products. Practical aspects of administration of blood products in the pre‐hospital environment, such as the need for an additional intravenous line, drawing blood samples for cross‐matching or warming of blood products before transfusion, can all be additional challenges in the pre‐hospital setting in which severely injured patients need to be treated with limited resources and limited personnel.

5. CONCLUSIONS {#tme12667-sec-0020}
==============

PHTRBC is increasingly used by civilian EMS, but a consensus on transfusion criteria is lacking. This scoping review summarises current practice and may provide the basis for consensus‐based pre‐hospital transfusion protocols. Some studies into the effects of PHTRBC on outcomes have been performed, and an overview of this data will be presented in the second part of this systematic review.
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